AKRX's NASDAQ Compliance Plan Accepted, Cellceutix, Viveve Make Big Moves

(RTTNews) - Akorn Inc.'s (AKRX) plan to regain compliance has been accepted by the Nasdaq Stock Market.

Since the company had not filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2015 with the SEC, it was notified of non-compliance by the Nasdaq on May 18, 2015, and was asked to submit a plan to regain compliance with Nasdaq listing rules within 60 days.

The plan to regain compliance with Nasdaq listing rules was submitted by Akorn on July 10, 2015.

The company has time until November 9, 2015 to file its Form 10-Q for the quarterly period ended March 31, 2015 and all other periodic reports required by listing rules.

AKRX closed Wednesday's trading at $44.30, down 0.96%.

Argos Therapeutics Inc.'s (ARGS) pivotal phase III clinical trial of AGS-003 in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma, dubbed ADAPT, has reached its enrollment goal of at least 450 randomized patients.

The company expects the next interim data review from the ADAPT trial in the first part of 2016.

ARGS closed Wednesday's trading at $6.49, down 1.67%.

Shares of Cellceutix Corp. (CTIX.OB) jumped more than 14% on Wednesday following the receipt of the FDA's Orphan Drug Designation by the company's drug candidate Kevetrin for the treatment of ovarian cancer.

Kevetrin is currently in a phase I clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center.

CTIX.OB closed Wednesday's trading 14.39% higher at $3.02.

Viveve Medical Inc.'s (VIVMF.OB) clinical study of its lead product Viveve System is on track to meet its primary efficacy and safety outcomes, as demonstrated by the 3-month positive interim results.

The study, dubbed VIVEVE I clinical study is a randomized, blinded and sham-controlled trial designed to demonstrate the efficacy of the Viveve Treatment versus a sham control procedure for the treatment of vaginal introital laxity.

Vaginal laxity is a condition resulting from the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction.

VIVMF.OB closed Wednesday's trading at $1.00, up 13.64%.